Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | HRH1 | P35367 | 2/20 | 0.56 |
| ▸ | TBXAS1 | P24557 | 7/20 | 0.56 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.53 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7549229 | 0.95 | TBXAS1 (0.55) | CYP2A6TDP1L3MBTL1HRH1TBXAS1 | |
| SCHEMBL7384270 | 0.95 | TBXAS1 (0.55) | CYP2A6TDP1L3MBTL1HRH1TBXAS1 | |
| SCHEMBL7692528 | 0.92 | TDP1 (0.63) | CYP2A6TDP1L3MBTL1HRH1TBXAS1 | |
| SCHEMBL8464889 | 0.92 | TBXAS1 (0.53) | CYP2A6TDP1L3MBTL1HRH1TBXAS1 | |
| SCHEMBL8464891 | 0.92 | TBXAS1 (0.53) | CYP2A6TDP1L3MBTL1HRH1TBXAS1 | |
| SCHEMBL7803183 | 0.90 | TDP1 (0.60) | CYP2A6TDP1L3MBTL1HRH1TBXAS1 | |
| SCHEMBL9522636 | 0.90 | TDP1 (0.60) | CYP2A6TDP1L3MBTL1HRH1TBXAS1 | |
| SCHEMBL5016747 | 0.89 | CHRNA7 (0.57) | CYP2A6TDP1L3MBTL1HRH1TBXAS1 | |
| SCHEMBL7164881 | 0.86 | TDP1 (0.59) | CYP2A6TDP1L3MBTL1HRH1TBXAS1 | |
| SCHEMBL9520426 | 0.86 | TDP1 (0.59) | CYP2A6TDP1L3MBTL1HRH1TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0872466-B1 | Process for the synthesis of 1,7-diaryl or 1,7-heteroarylheptan-4-ols and synthetic intermediates | FABBRICA ITALIANA SINTETICI SPA (IT) | 2002-01-30 | — | — | EP | claimed |
| US-5973157-A | Process for the synthesis of 1,7-diarly or heteroaryl-heptane-4-ols and new synthetic intermediates | F.I.S. FABBRICA ILTALIANA SINTETICI S.P.A. (IT) | 1999-10-26 | — | — | US | claimed |
| EP-0872466-A1 | Process for the synthesis of 1,7-diaryl or 1,7-heteroarylheptan-4-ols and synthetic intermediates | F.I.S. FABBRICA ITALIANA SINTETICI S.p.A. (IT) | 1998-10-21 | — | — | EP | claimed |
| EP-3030556-B1 | SELECTIVE FKBP51 LIGANDS FOR TREATMENT OF PSYCHIATRIC DISORDERS | UNIV DARMSTADT TECH (DE) | 2019-10-30 | — | — | EP | disclosed |
| US-10246413-B2 | Selective FKBP51 ligands for treatment of psychiatric disorders | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2019-04-02 | — | — | US | disclosed |
| US-20180072667-A1 | SELECTIVE FKBP51 LIGANDS FOR TREATMENT OF PSYCHIATRIC DISORDERS | HAUSCH, FELIX (DE) | 2018-03-15 | — | — | US | disclosed |
| US-20180072667-A1 | SELECTIVE FKBP51 LIGANDS FOR TREATMENT OF PSYCHIATRIC DISORDERS | HAUSCH, FELIX (DE) | 2018-03-15 | — | — | US | disclosed |
| US-9845292-B2 | Selective FKBP51 ligands for treatment of psychiatric disorders | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2017-12-19 | — | — | US | disclosed |
| US-9845292-B2 | Selective FKBP51 ligands for treatment of psychiatric disorders | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2017-12-19 | — | — | US | disclosed |
| US-20160289184-A1 | SELECTIVE FKBP51 LIGANDS FOR TREATMENT OF PSYCHIATRIC DISORDERS | HAUSCH, FELIX (DE) | 2016-10-06 | — | — | US | disclosed |
| US-20160289184-A1 | SELECTIVE FKBP51 LIGANDS FOR TREATMENT OF PSYCHIATRIC DISORDERS | HAUSCH, FELIX (DE) | 2016-10-06 | — | — | US | disclosed |
| US-5973157-A | Process for the synthesis of 1,7-diarly or heteroaryl-heptane-4-ols and new synthetic intermediates | F.I.S. FABBRICA ILTALIANA SINTETICI S.P.A. (IT) | 1999-10-26 | — | — | US | disclosed |
| EP-0941113-A1 | METHODS AND COMPOSITIONS FOR STIMULATING NEURITE GROWTH USING COMPOUNDS WITH AFFINITY FOR FKBP12 IN COMBINATION WITH NEUROTROPHIC FACTORS | Vertex Pharmaceuticals Incorporated (US) | 1999-09-15 | — | — | EP | disclosed |
| WO-1999010340-A1 | COMPOUNDS POSSESSING NEURONAL ACTIVITY | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1999-03-04 | — | — | WO | disclosed |
| EP-0872466-A1 | Process for the synthesis of 1,7-diaryl or 1,7-heteroarylheptan-4-ols and synthetic intermediates | F.I.S. FABBRICA ITALIANA SINTETICI S.p.A. (IT) | 1998-10-21 | — | — | EP | disclosed |
| US-5780484-A | Methods for stimulating neurite growth with piperidine compounds | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1998-07-14 | — | — | US | disclosed |
| WO-1998020893-A1 | METHODS AND COMPOSITIONS FOR STIMULATING NEURITE GROWTH USING COMPOUNDS WITH AFFINITY FOR FKBP12 IN COMBINATION WITH NEUROTROPHIC FACTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1998-05-22 | — | — | WO | disclosed |
| US-5744485-A | INCREASE SENSITIVITY OF CELLS; CANCER | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1998-04-28 | — | — | US | disclosed |
| EP-0754176-A1 | NOVEL CARBAMATES AND UREAS AS MODIFIERS OF MULTI-DRUG RESISTANCE | Vertex Pharmaceuticals Incorporated (US) | 1997-01-22 | — | — | EP | disclosed |
| WO-1995026337-A1 | NOVEL CARBAMATES AND UREAS AS MODIFIERS OF MULTI-DRUG RESISTANCE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1995-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072667-A1 | SELECTIVE FKBP51 LIGANDS FOR TREATMENT OF PSYCHIATRIC DISORDERS | FKBP5, FKBP1A, FKBP3 | CYP2A6 2095/4885TDP1 615/4885L3MBTL1 2374/4885 |
| US-10246413-B2 | Selective FKBP51 ligands for treatment of psychiatric disorders | FKBP5, FKBP1A, FKBP3 | CYP2A6 2095/4885TDP1 615/4885L3MBTL1 2374/4885 |
| US-20160289184-A1 | SELECTIVE FKBP51 LIGANDS FOR TREATMENT OF PSYCHIATRIC DISORDERS | FKBP5, FKBP1A, FKBP1B | CYP2A6 1443/4885TDP1 704/4885L3MBTL1 3157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.